At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 396 target
Drug / intervention
LBL-024 for Injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors
In Brief
A Phase 2 clinical trial evaluating LBL-024 for Injection for Advanced Solid Tumor. Currently recruiting, targeting 396 participants across 49 sites.
Signals
Enrolling ahead of pace
Detailed Summary
To evaluate the phase I/II clinical study of LBL-024 in the treatment of patients with advanced malignant tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
202220232024202520262027
First PostedDec 2021
Enrollment StartJan 2022
TodayJul 2026
Primary CompletionDec 2026
First PostedDec 28, 2021
Enrollment StartJan 6, 2022
Primary CompletionDec 1, 2026
TodayJul 1, 2026
Enrollment to primary: 4.9 yearsPosted 4.5 years agoPrimary completion in 5 months
Interventions
LBL-024 for Injectiondrug
LBL-024 was given every three weeks for treatment